Timothy M. Chlon, PhD

Scaffolding-dependent CASP1 constrains excessive cell-intrinsic inflammatory signaling in leukemia. Uible, EE; Choi, I; Clough, CA; Hassan, A; Anandappa, AJ; Fisher, J; Karki, B; Hueneman, K; Choi, K; Vick, EJ; Pasare, C; Cunningham, JT; Volk, AG; Starczynowski, DT. Cell Chemical Biology. 2026; 33(1):59-73.e10.

Decoding DDX41: Clinical impact of germline and somatic mutations in 77 high-risk myeloid neoplasm patients. Badar, T; Kumar, M; Kusne, Y; Lasho, T; Foran, J; Murthy, H; Kharfan-Dabaja, M; Chlon, T; Gangat, N; Alkhateeb, H; Ferrer, A; Litzow, M; Al-Kali, A; Patnaik, M. Blood. 2025; 146(Supplement 1):1442.

The somatic DDX41 hot spot mutation (p.R525H) causes skewed differentiation into plasmacytoid dendritic cells in human iPSC and leukemia models. Kida, J; Fricker, M; Stepanchick, E; Kusne, Y; Badar, T; Lasho, T; Patnaik, M; Chlon, T. Blood. 2025; 146(Supplement 1):678-678.

The somatic hotspot mutation of DDX41 (p.R525H) elicits dominant-negative effects upon non-truncating germline variants, explaining similar disease risk as truncating variants. Fisher, J; Stepanchick, E; Wilson, A; Kida, J; Badar, T; Lasho, T; Kusne, Y; Patnaik, M; Chlon, T. Blood. 2025; 146(Supplement 1):3221-3221.

Prevalence of cytopenia(s) and somatic variants in patients with DDX41 mutant germline predisposition syndrome. Kusne, Y; Badar, T; Lasho, T; Marando, L; Mangaonkar, AA; Finke, C; Foran, JM; Al-Kali, A; Palmer, J; Arana Yi, C; Litzow, MR; Chlon, T; Ferrer, A; Patnaik, MM. British Journal of Haematology. 2025; 206(4):1109-1120.

Germline DDX41 mutations in myeloid neoplasms: the current clinical and molecular understanding. Kida, J; Chlon, TM. Current Opinion in Hematology. 2025; 32(2):67-76.

The Most Common Somatic DDX41 Mutation (p.R525H) Causes Loss of an Essential Function and Is Selected Against in Human iPSC and Leukemia Models. Kida, J; Fricker, M; Stepanchick, E; Chlon, T. Blood. 2024; 144(Supplement 1):4089-4089.

Prevalence and Clinical Features of Non-Myeloid Neoplasms in Patients with DDX41 Mutant Germline Predisposition Syndrome. Kusne, Y; Badar, T; Lasho, TL; Marando, L; Mangaonkar, AA; Finke, C; Foran, JM; Al-Kali, A; Alkhateeb, HB; Gangat, N; Litzow, MR; Chlon, T; Ferrer, A; Patnaik, MM. Blood. 2024; 144(Supplement 1):440-440.

Clinical Characteristics of Myeloproliferative Neoplasms in Patients with DDX41 MT Germline Predisposition Syndrome. Kusne, Y; Badar, T; Lasho, TL; Marando, L; Mangaonkar, AA; Finke, C; Foran, JM; Al-Kali, A; Alkhateeb, HB; Gangat, N; Tefferi, A; Chlon, T; Ferrer, A; Patnaik, MM. Blood. 2024; 144(Supplement 1):3183-3183.

Absence of PNH-clones in DDX41mutant-GPS aids in their distinction from acquired BM failure syndromes. Kusne, Y; Badar, T; Lasho, T; Ferrer, A; Mangaonkar, AA; Finke, C; Marando, L; Foran, JM; Al-Kali, A; Alkhateeb, HB; Chlon, T; Patnaik, MM. Leukemia Research. 2024; 145:107561.